for of four-pillar talented drug clinical a record record employees hiring device XXX quality, the team Thanks, year our and headlined volume million, cases growth case delivery medical and across by new both strategy product successful legal new Danilo. supported of support. successful development, of was partnerships revenue in and our XXXX $XX.X across businesses our
into our that break pillars. Let’s progress growth four down
a First, continued more multiple have the approximately every pharma than and new approximately additional XX XXXX. team partner at services month. start XX delivery one academic currently our up and throughout pace We biologics individual across and indications, to XXXX, from partnerships add of of partners drug
or drug has their reminder, to one own, a As planning for or each platform customer common it of meaning a they only that vector a drug indication. are is not their partner use
in an XXXX, partners business Our approval European-based to gene United could the still decision Europe initial has in neuro that and therapy to us in Europe continue researchers. additional into or States. either expand believe win take and plan adding commercial for academic already to helped place pharma We
continue existing clinical the year. addition, progress calendar partners to plan trials our patients to initiate regulatory new In and pathway through clinical and in this
XXXX business here continue segment drug biologics in new hires new fastest-growing productivity and our the delivery our be talented many team, and XXXX. expect add services to to we to in and continue to Our
options in patients patient first. for volume program we put Second, headwinds navigation deep educate well, patients. with about neurosurgery our families functional business XXXX case Omicron At record Delta as first the expanded to variants elective treatment. and their achieving the our impacting and and procedures. created ClearPoint, the despite Starting brain designed We revenue by always launched our stimulation
platform. speak to DBS each under the So MRI-guided encourage which an we would room be appropriate patient. could technique anesthesia offer general each and using operating treatment directly future, MER-guided the match the devices current procedure for options, both physician ClearPoint procedures In alternatives, hospital in awake, to to their ClearPoint about or plans each for allowing performed the every individual with surgeon patient
hospitals ClearPoint options and standpoint, the progress available in members to surgeons portfolio early have schedules them. budgets, solidified a From continued Neuro team portfolio, With both the XXXX. we across infusion using will our and and significant capital development
clinical to cross on mentioned the quarter of call, FDA we last software the over is receive in the to first array FDA and SmartFrame help the complete room. and which the supporting the of workflows system array module ClearPoint clearance XXXX. into our operating did software the have preplanning array, second Subsequently, use our to in meant As expect for we streamline submitted and fourth half
We development in Blackrock, continued collaboration well, as with Revolution Maestro MER head our robotic-assisted software, D&K our years, space. improved exciting of multi have Brain and as that few companies Orchestra in continue system rest of Engineering. co-developed have an in frame, our the over the We next called neurosurgery and one X.X cadence system trajectory the the ClearPoint the the innovative including will across pipeline Model, new demonstrate partnership to ClearPoint we feel with true the which of products
using which and and cases was SmartFrame X.X in in of we Maestro Revolution intact, cases first continue to quarter here clinical completing of in remain XXXX. clinical our XXXX and second the Array, ClearPoint cases and lines XXXX, time Orchestra, accomplished expect first of X.X, previous Our Array MER software after first
where There’s to in place medical with date cortical purposes, BCI recent in significant exciting to leveraging future surgeons this and experienced we hospital existing for very of make navigation one infusion partners, interface placing custom a drug. that’s subjects very business system, of the a Our XX the seven we the platform approximately implant most that taking we space. similar around and disposables our we agreement, more SmartFrame solution do pharma across is of investment announcement can past during both repeatable similar. ClearPoint BCI our of and tremendous the work instead clinical Blackrock the cannula, and Neurotech This the build target support one. to provide BCI potential years. enter this first centers. completed faster, are and more are to Under the a infusion brain is by is as segment In companies software example, precise you is but the with BCI, the the multiple at with a human this very implantation and relationship tell partnership the communication Blackrock to implants over computer
commercial channel hospitals navigation spoke the ClearPoint is through platform our on to and hub. to as another system disposable this see intention directly sell Our this
of every ClearPoint XXXX. excellence Another expect BCI future, the currently neurosurgery should the sometime and cases the SmartFrame have modern in of clinical in we reason first that
while used MRI for many, room. surgery not designed take importantly, place applications, are if in is all, Now BCI the the to itself operating images
into ClearPoint So technology an is MRI this are on rather that additional crossover on not room. but the for focused application reliant we access that is today another operating
we make development in pillar, system and have schedule is remain our continued and Sweden ClearPoint laser our our previously communicated our that For The therapeutic continues exclusive lines. with progress. for access on progress third CLS products time in to devices, development ablation
the and continue team we to our cases the expect fourth clinical to predicted, quarter complete FDA here did first XXXX, solution the previously to be collaborative of XXXX. in As in performed submit our
applied technologies Access across of conditional inventory procedures as We estimated prototypes ablation, in case date them in delivery beauty with more This biopsy biologics same also MRI from important have the entire version the sometime well in is even ClearPoint to and indications, more stimulation, ablation received brain note two biopsy, predictable, they enabling Pillar two crucial and in to the training our entire – first the we of to that important in investment on drill case, release perhaps operating our and to portfolio to drill our the adeor a track more case XXXX of Similarly, important, standpoint products. in in are deep future. a do enter brain biologics, of XXXX. to expect system platform including release preparing XXXX. the That an evaluate hospital navigation It a access solutions procedures from is of laser day mentioned room fact, are laser the that is here designed of to market drug strategy MRI full with is investment these the version into remain centers in to computer as portfolio perform faster DDS PCI they like our as because Every with and and are our or a and suite. of interfaces are across technologies as therapeutic biologics partnership make the cases is, the much adeor more and applies training many our well. as future. as does the majority today
has our achieving pillar Finally, as well. made fourth of progress global scale
in regulations. This Europe small enough rules been of has have into that has not certain companies be MDR the that new decided products they Our daunting sell year. and the quality effect in under updated system been in with compliant some a is past task went to to May to successfully new these European not
and present of clinical we at that biologics surveillance, is post-market and our us an helps we giving simple the provide to with advantage Although service have we challenging, our our fact compliance device and the and medical specialists an that investment additional procedures that is clinical right us one, believe can compliance one partners.
current for in have and to be and We important market with for Israel of devices achieved therapies there an biologics, approval suite using delivery navigation products our trials new and a performed Israel. products is and will across enable also innovation presence our drug having ClearPoint.
successful chain securing the ahead been and real far of quite in have supply thus very additional challenging. backlog are that inventory We
expansion many vast can you materials with. time, base We has previously our materials of the our our purchase United our although supply ahead balance our and challenge of majority distraction existing team is have The on is the used vendors domestic, source of sheet. to device States, dealing capital inventory that which by daily raw see investment company currently is which of a outside about and every just mentioned, of
margins gross Our and very closely XX%, hover these it’s watch pressures. that continue inflationary something we will near geographical given to and
future cannot. sheer If those which and one across in quite These one were all markets, million-plus the of technology, results annually. take has to individual opportunity will way are lines, up today product therapy course, patients is Today, treated develop, with have each estimated but is year. $XX we global potential more XX indications, you new a market than number working diversified directly billion include of million diagnosed actively enabling time many in technologies ClearPoint partnerships the and opportunities of that excess to our of ClearPoint the more add we the through If on or patients current are all than different impressive. partnerships
$XX XX% XXXX corresponds to between to of full point, of At year and the ways positively patient between our many and have impact large $XX full are this for reiterating which a million win to million, We guidance and XX% we revenue growth lives. year. number
alone. this a million, plan at in $XX of capital continue we achieve balance important We ample start was raise the our year the to to we do hand and excess not to programs of have Our milestones on value-creating of that year. cash this believe additional year cash and number
million impact the of include Our risks. to million $XX revenue does $XX of guidance certain
have on March elective Omicron and First, itself new had start procedures the month month modest this procedures impact transient impact any that year in and resolve is of a we assume that this the lasts on of a will that elective will for variants or at two.
Second, no issues orders place supply our for assume issues our back products. or chain our or but that therapeutic that to meaningful for persist, supply product partners’ customers we take
geopolitical cetera. installations, travel, very new issues overcrowding, material the predict costs, et Finally, to are to hospital difficult relative
So yet guidance. not that not and that understood risk in is included
assuming Our position the today’s of million very current as very $XX.X close risks hand and baseline, a not significant on a I operations uncertain is cash would XXXX which the our important in second cash is is cash years have just annualized, all obviously then Despite environment. advantage burn half fund even to of that four our about mentioned, which operational is growth, to we take – you ClearPoint intention. if zero of from difficult for
Our careful With weather aspects growth financing and cash will storm of our four-pillar like any to to key that, open to questions. the not I and this management call would up strategy us strategy. help sacrifice the
